Policy & Regulation
Q-linea announces global, exclusive partnership with Thermo Fisher Scientific for commercialisation of ASTar
13 February 2020 -

Infectious disease diagnostics specialist Q-linea AB (STO:QLINEA) announced on Wednesday that it has entered into a worldwide exclusive partnership with Thermo Fisher Scientific Inc (NYSE:TMO), a provider of scientific services, for the commercialisation of ASTar.

ASTar, Q-linea's lead product, is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture.

Under this partnership, Thermo Fisher Scientific will have the exclusive right to offer ASTar to the market in all geographies, with the exception that Q-linea can serve the Swedish market. This partnership is exclusive to both companies regarding fast AST testing.

Also, the two companies will work closely together to provide customers with a comprehensive AST portfolio.

Thermo Scientific Sensititre Complete Automated AST System is the industry standard for traditional MIC determination. Combining Thermo Fisher's tradition, experience and strength in the field, together with Q-linea's unique system for rapid and fully automatic AST analysis is expected to greatly improve and speed up the diagnosis for patients with severe infectious diseases.

Q-linea is a research, development and manufacturing company that primarily develops instruments and disposables for rapid and reliable infection diagnostics.